<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00813072</url>
  </required_header>
  <id_info>
    <org_study_id>PEP0206</org_study_id>
    <secondary_id>EudraCT number: 2006-006452-35</secondary_id>
    <nct_id>NCT00813072</nct_id>
  </id_info>
  <brief_title>Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma</brief_title>
  <official_title>A Randomized Phase II Study of PEP02, Irinotecan or Docetaxel as a Second Line Therapy in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaEngine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaEngine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess objective tumor response in the single agent treatment
      of PEP02, irinotecan, or docetaxel for locally advanced or metastatic gastric or
      gastroesophageal junction adenocarcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Palliative chemotherapy has been shown to improve survival compared with best supportive care
      alone in patients with unresectable or recurrent gastric cancer. There is no standard
      second-line chemotherapy for advanced gastric cancer and no randomized-controlled trial data
      suggest a benefit of second-line chemotherapy compared with supportive care alone. Response
      rates of second-line therapy in phase II trials are similar to those seen for other cancers
      that are more commonly retreated. Combination therapy may achieve higher response rates than
      single agents, however, the survival outcome are the same. In addition, data suggest that
      patients may obtain symptomatic benefits from second-line therapy. In comparison to the
      toxicity profile of single agent with combination regimen, patients are more tolerable to
      single agent therapy than combination.

      Based on the previous clinical experience in second line chemotherapy of advanced gastric
      cancer, the single agent of PEP02, irinotecan and docetaxel are selected as the regimens for
      this randomized phase II study. The efficacy and toxicity outcome of the three-arm design
      will be a valuable reference for future combination therapy or phase III study design.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective tumor response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival, duration of tumor response, time to progression, time to treatment failure, disease control rate, 1-year survival rate,and overall survival; pharmacokinetics and pharmacogenetics of PEP02 and irinotecan</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Stomach Neoplasms</condition>
  <condition>Esophageal Neoplasms</condition>
  <arm_group>
    <arm_group_label>1. PEP02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>liposome irinotecan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. irinotecan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3. docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP02</intervention_name>
    <description>120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 day as a treatment cycle.
Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>1. PEP02</arm_group_label>
    <other_name>liposome irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan</intervention_name>
    <description>300 mg/m2, IV infusion on day 1 of each 21 day as a treatment cycle. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>2. irinotecan</arm_group_label>
    <other_name>Campto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>75 mg/m2, IV infusion for 60 minutes on day 1 of each 21 day as a treatment cycle.
Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>3. docetaxel</arm_group_label>
    <other_name>Taxetere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed locally advanced (unresectable) or
             metastatic adenocarcinoma of gastric or gastroesophageal junction

          -  Failed to only one systemic chemotherapy for locally advanced or metastatic disease,
             including patients whose diseases recur within 6 months after (neo)adjuvant
             chemotherapy. Chemotherapy administered with concurrent radiotherapy is NOT considered
             as systemic chemotherapy.

          -  Have at least one measurable lesion according to the RECIST criteria

          -  Aged above or equal to 18 years, at the time of acquisition of informed consent

          -  With ECOG performance status 0, 1, or 2

          -  Life expectancy equal to or more than 3 months

          -  With adequate organ and marrow function as defined below:

          -  With ability to understand and the willingness to sign a written Informed Consent Form

        Exclusion Criteria:

          -  Had systemic chemotherapy within 3 weeks before the commencement of study treatment

          -  Had radiotherapy within 4 weeks before the commencement of study treatment

          -  With known brain metastasis

          -  With active multiple cancers or had treatment for other carcinomas within the last
             five years, except cured non-melanoma skin and treated in-situ cervical cancer

          -  With prior irinotecan or taxane (paclitaxel, docetaxel) treatment

          -  Have received irradiation affecting &gt; 30% of the active bone marrow

          -  Had major surgery within 4 weeks of the start of study treatment (laparotomy, line
             placement is not considered major surgery)

          -  Have not recovered from prior treatments

          -  With preexisting peripheral neuropathy &gt; grade 2

          -  With history of allergic reaction to liposome product or other drugs formulated with
             polysorbate

          -  With uncontrolled intercurrent illness including, but not limited to, ongoing or
             active infection, symptomatic congestive heart failure, active gastrointestinal
             bleeding, watery stools, central nervous system disorders or psychiatric
             illness/social situation that would limit compliance with study requirements or judged
             to be ineligible for the study by the investigator

          -  Have received any investigational agents within 3 weeks preceding the start of study
             treatment

          -  Pregnant or breastfeeding females (a pregnancy test must be performed on all female
             patients who are of child-bearing potential before entering the study, and the result
             must be negative)

          -  With intestinal obstruction

          -  Have received St. John's Wort, CYP3A4 inducing anticonvulsants (phenytoin,
             phenobarbital, and carbamazepine), rifampin and rifabutin within two weeks, or
             ketoconazole, itraconazole, troleandomycin, erythromycin, diltiazem and verapamil
             within one week before the administration of study medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cunningham</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal Marsden Hospital, London &amp; Surrey, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Hospital Mostar</name>
      <address>
        <city>Mostar</city>
        <zip>36 000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre University of Sarajevo</name>
      <address>
        <city>Sarajevo</city>
        <zip>71 000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Centre Rijeka</name>
      <address>
        <city>Rijeka</city>
        <zip>51 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Centre Dubrava</name>
      <address>
        <city>Zagreb</city>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Centre Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Seoul</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cl√≠nico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Chiayi</name>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - LinKou</name>
      <address>
        <city>LinKou</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>25115</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital Oncology Center</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's &amp; St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE19RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kent Oncology Centre, Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>Surrey</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
    <country>Croatia</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2008</study_first_posted>
  <last_update_submitted>March 1, 2012</last_update_submitted>
  <last_update_submitted_qc>March 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>Stomach Cancer</keyword>
  <keyword>Gastroesophageal</keyword>
  <keyword>Gastroesophageal Junction</keyword>
  <keyword>Esophageal Cancer</keyword>
  <keyword>phase II</keyword>
  <keyword>PEP02</keyword>
  <keyword>randomization</keyword>
  <keyword>randomisation</keyword>
  <keyword>adenocarcinoma</keyword>
  <keyword>locally advanced</keyword>
  <keyword>metastatic</keyword>
  <keyword>simon's two</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

